{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(1)"],"submitter":["Ueki H"],"pubmed_abstract":["Recently, immune checkpoint inhibitor (ICI) based combination therapies, including anti-PD-1 antibody, nivolumab with anti-CTLA-4 antibody, and ipilimumab have become the primary treatment option for metastatic or unresectable renal cell carcinoma (RCC). However, despite the combination of two ICIs, 60-70% of patients are still resistant to first-line cancer immunotherapy. In the present study, undertook combination immunotherapy for RCC using an oral cancer vaccine (Bifidobacterium longum displaying WT1 tumor associated antigen (B. longum 420)) with anti-PD-1 and anti-CTLA-4 antibodies in a mouse syngeneic model of RCC to explore possible synergistic effects. We found that B. longum 420 significantly improved the survival of mice bearing RCC tumors treated by anti-PD-1 and anti-CTLA-4 ant"],"journal":["Scientific reports"],"pagination":["9994"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10281997"],"repository":["biostudies-literature"],"pubmed_title":["An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model."],"pmcid":["PMC10281997"],"pubmed_authors":["Fujisawa M","Furukawa J","Shirakawa T","Terakawa T","Hara T","Kitagawa K","Kato M","Yanase S","Nakano Y","Ueki H","Okamura Y","Bando Y"],"additional_accession":[]},"is_claimable":false,"name":"An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model.","description":"Recently, immune checkpoint inhibitor (ICI) based combination therapies, including anti-PD-1 antibody, nivolumab with anti-CTLA-4 antibody, and ipilimumab have become the primary treatment option for metastatic or unresectable renal cell carcinoma (RCC). However, despite the combination of two ICIs, 60-70% of patients are still resistant to first-line cancer immunotherapy. In the present study, undertook combination immunotherapy for RCC using an oral cancer vaccine (Bifidobacterium longum displaying WT1 tumor associated antigen (B. longum 420)) with anti-PD-1 and anti-CTLA-4 antibodies in a mouse syngeneic model of RCC to explore possible synergistic effects. We found that B. longum 420 significantly improved the survival of mice bearing RCC tumors treated by anti-PD-1 and anti-CTLA-4 ant","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2025-04-22T08:40:03.19Z","creation":"2025-04-05T22:36:05.838Z"},"accession":"S-EPMC10281997","cross_references":{"pubmed":["37340017"],"doi":["10.1038/s41598-023-37234-6"]}}